Dr. John Cush RheumNow
5 years 2 months ago
A prospective, longitudinal study of the cognitive development of children born to mothers with rheumatoid arthritis (RA) demonstrates normal development as measured by comparative school test scores.
https://t.co/6Dfdnin1aI https://t.co/rJFn9WuCgO
Dr. John Cush RheumNow
5 years 2 months ago
AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the FDA for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
https://t.co/22HVA32IAh https://t.co/xZNfepcDLQ
k dao KDAO2011
5 years 2 months ago
Don't forget to register for the ACR Virtual Townhall Wednesday 8/4/21: 7 PM ET
Re: COVID vaccination effectiveness for rheum patients w/real world data
@ACRheum @alhkim @rheum_cat
https://t.co/CKAwSLMv8R
Dr. John Cush RheumNow
5 years 2 months ago
"Fibromyalgianess" is highlighted as a risk factor for undue, extended glucocorticoid use in rheumatoid arthritis (RA) patients, according to Wallace and colleagues in Rheumatology.
https://t.co/uv19GSZsBV https://t.co/aSFlV9zeGt
Seminars in Arthritis and Rheumatism seminarthrheum
5 years 2 months ago
Article in press:
Can ANCA titers predict relapse in patients with GPA?
Cohort study by @UofT_DoM
- microscopic hematuria and MPO ab at month 12 predicted increased risk of relapse
https://t.co/ks3Gj5iSLR
Dr. John Cush RheumNow
5 years 2 months ago
Study from the UK BSRBR for #AS & 2043 pts showed 44% w/ at least 1 comorbidity. Each comorbidity was associated w/ 0.40 unit increase in BASDAI and 0.53 in spinal pain. More Dz activity w/ Depression, CHF and peptic ulcer, not CRP/ESR https://t.co/0vAnbjHicw
A prospective, longitudinal study of the cognitive development of children born to mothers with rheumatoid arthritis (RA) demonstrates normal development as measured by comparative school test scores.
Dr. John Cush RheumNow
5 years 2 months ago
FDA Approves Anifrolumab in active, moderate-severe SLE on background standard of care therapies. https://t.co/22HVA32IAh https://t.co/NxJ4sWTWfE
AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
Dr. John Cush RheumNow
5 years 2 months ago
Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.
https://t.co/Uu1VjAbKMi https://t.co/uGvTyLExjf
Dr. John Cush RheumNow
5 years 2 months ago
The ARTIS Study Group has published their analysis of (non-skin) cancer risk in rheumatoid arthritis, claiming the overall safety of biologic DMARDs and targeted synthetic DMARDs (tsDMARDs).
https://t.co/RNWrLR53Wx https://t.co/mMmKKrX9vx
Dr. John Cush RheumNow
5 years 2 months ago
Health personnel (HCP) @ long-term care facilities (LTCFs) are at high risk for COVID-19. March 2021, 57% of LTCF HCPs were vaccinated. COVID-19 vax was highest in MDs (75.1%); lowest nurses (56.7%) & aides (45.6%). https://t.co/VjHutcrh26 https://t.co/8aO1mFgC8f
Dr. John Cush RheumNow
5 years 2 months ago
ICYMI: The FDA has authorized baricitinib ALONE as treatment for COVID-19 hospitalized adults and pediatric patients requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) https://t.co/WMc78GmOLU https://t.co/Bp5tL4pRk5
Dr. John Cush RheumNow
5 years 2 months ago
Worth another share--
Turning the Corner on CV Risk in Rheumatoid Arthritis by Richard Conway ( @RichardPAConway) #EULAR2021
https://t.co/S0ownscRKv https://t.co/7QtynRKAd6
Dr. John Cush RheumNow
5 years 2 months ago
ICYMI: One of our top June videos
WATCH: Is blindness with Tocilizumab in GCA a worry?
Dr. David Liew ( @drdavidliew ) weighs in. #EULAR2021
https://t.co/eFrmbkW9Gy https://t.co/4tY3hEDj2j
